152 related articles for article (PubMed ID: 24121993)
21. Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity.
Gong J; Sachdev E; Mita AC; Mita MM
World J Methodol; 2016 Mar; 6(1):25-42. PubMed ID: 27019795
[TBL] [Abstract][Full Text] [Related]
22. Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors.
Gollamudi R; Ghalib MH; Desai KK; Chaudhary I; Wong B; Einstein M; Coffey M; Gill GM; Mettinger K; Mariadason JM; Mani S; Goel S
Invest New Drugs; 2010 Oct; 28(5):641-9. PubMed ID: 19572105
[TBL] [Abstract][Full Text] [Related]
23. Oncolytic reovirus therapy: Pilot study in dogs with spontaneously occurring tumours.
Hwang CC; Igase M; Sakurai M; Haraguchi T; Tani K; Itamoto K; Shimokawa T; Nakaichi M; Nemoto Y; Noguchi S; Coffey M; Okuda M; Mizuno T
Vet Comp Oncol; 2018 Jun; 16(2):229-238. PubMed ID: 29076241
[TBL] [Abstract][Full Text] [Related]
24. Oncolytics Biotech
Thompson B
Melanoma Manag; 2015 May; 2(2):105-107. PubMed ID: 30190838
[TBL] [Abstract][Full Text] [Related]
25. Single Amino Acid Differences between Closely Related Reovirus T3D Lab Strains Alter Oncolytic Potency
Mohamed A; Clements DR; Gujar SA; Lee PW; Smiley JR; Shmulevitz M
J Virol; 2020 Jan; 94(4):. PubMed ID: 31748391
[TBL] [Abstract][Full Text] [Related]
26. Modification of mammalian reoviruses for use as oncolytic agents.
Van Den Wollenberg DJ; Van Den Hengel SK; Dautzenberg IJ; Kranenburg O; Hoeben RC
Expert Opin Biol Ther; 2009 Dec; 9(12):1509-20. PubMed ID: 19916732
[TBL] [Abstract][Full Text] [Related]
27. Immune characterization of metastatic colorectal cancer patients post reovirus administration.
Parakrama R; Fogel E; Chandy C; Augustine T; Coffey M; Tesfa L; Goel S; Maitra R
BMC Cancer; 2020 Jun; 20(1):569. PubMed ID: 32552875
[TBL] [Abstract][Full Text] [Related]
28. Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.
Stoeckel J; Hay JG
Curr Opin Mol Ther; 2006 Jun; 8(3):249-60. PubMed ID: 16774045
[TBL] [Abstract][Full Text] [Related]
29. A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial.
Jonker DJ; Tang PA; Kennecke H; Welch SA; Cripps MC; Asmis T; Chalchal H; Tomiak A; Lim H; Ko YJ; Chen EX; Alcindor T; Goffin JR; Korpanty GJ; Feilotter H; Tsao MS; Theis A; Tu D; Seymour L
Clin Colorectal Cancer; 2018 Sep; 17(3):231-239.e7. PubMed ID: 29653857
[TBL] [Abstract][Full Text] [Related]
30. Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma.
Jaime-Ramirez AC; Yu JG; Caserta E; Yoo JY; Zhang J; Lee TJ; Hofmeister C; Lee JH; Kumar B; Pan Q; Kumar P; Baiocchi R; Teknos T; Pichiorri F; Kaur B; Old M
Mol Ther Oncolytics; 2017 Jun; 5():87-96. PubMed ID: 28812060
[TBL] [Abstract][Full Text] [Related]
31. Oncolytic Viral Therapy Using Reovirus.
Thirukkumaran C; Morris DG
Methods Mol Biol; 2015; 1317():187-223. PubMed ID: 26072409
[TBL] [Abstract][Full Text] [Related]
32. Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity.
Ilett EJ; Prestwich RJ; Kottke T; Errington F; Thompson JM; Harrington KJ; Pandha HS; Coffey M; Selby PJ; Vile RG; Melcher AA
Gene Ther; 2009 May; 16(5):689-99. PubMed ID: 19282847
[TBL] [Abstract][Full Text] [Related]
33. Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization.
Ilett EJ; Bárcena M; Errington-Mais F; Griffin S; Harrington KJ; Pandha HS; Coffey M; Selby PJ; Limpens RW; Mommaas M; Hoeben RC; Vile RG; Melcher AA
Clin Cancer Res; 2011 May; 17(9):2767-76. PubMed ID: 21389099
[TBL] [Abstract][Full Text] [Related]
34. Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.
Heinemann L; Simpson GR; Boxall A; Kottke T; Relph KL; Vile R; Melcher A; Prestwich R; Harrington KJ; Morgan R; Pandha HS
BMC Cancer; 2011 Jun; 11():221. PubMed ID: 21645351
[TBL] [Abstract][Full Text] [Related]
35. Reovirus 3 not detected by reverse transcriptase-mediated polymerase chain reaction analysis of preserved tissue from infants with cholestatic liver disease.
Steele MI; Marshall CM; Lloyd RE; Randolph VE
Hepatology; 1995 Mar; 21(3):697-702. PubMed ID: 7533124
[TBL] [Abstract][Full Text] [Related]
36. Oncolytic viral therapy using reovirus.
Thirukkumaran C; Morris DG
Methods Mol Biol; 2009; 542():607-34. PubMed ID: 19565924
[TBL] [Abstract][Full Text] [Related]
37. Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts.
Hingorani P; Zhang W; Lin J; Liu L; Guha C; Kolb EA
Cancer; 2011 Apr; 117(8):1764-74. PubMed ID: 21472724
[TBL] [Abstract][Full Text] [Related]
38. Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors.
Roulstone V; Khan K; Pandha HS; Rudman S; Coffey M; Gill GM; Melcher AA; Vile R; Harrington KJ; de Bono J; Spicer J
Clin Cancer Res; 2015 Mar; 21(6):1305-12. PubMed ID: 25424857
[TBL] [Abstract][Full Text] [Related]
39. Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants.
Mohamed A; Johnston RN; Shmulevitz M
Viruses; 2015 Dec; 7(12):6251-78. PubMed ID: 26633466
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.
Galanis E; Markovic SN; Suman VJ; Nuovo GJ; Vile RG; Kottke TJ; Nevala WK; Thompson MA; Lewis JE; Rumilla KM; Roulstone V; Harrington K; Linette GP; Maples WJ; Coffey M; Zwiebel J; Kendra K
Mol Ther; 2012 Oct; 20(10):1998-2003. PubMed ID: 22871663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
